Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Feb 3;9(1):e002851. doi: 10.1136/rmdopen-2022-002851

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Interleukin (IL)−17A (IL17A) vaccine induces antibody production in a spondyloarthritis (SpA) model in human leucocyte antigen (HLA)-B27 transgenic rats. (A) Targeted sequences of IL17A vaccine are shown. (B) Experimental protocol for IL17A vaccination of the inactivated Mycobacterium Tuberculosis (MT)-induced SpA model in HLA-B27 transgenic rats. The epitope was conjugated with keyhole limpet hemocyanin (KLH). KLH-conjugated IL17A vaccine was injected with an alum adjuvant. HLA-B27 transgenic rats were immunised with the IL17A vaccine with KLH or KLH only intracutaneously thrice every 2 weeks. Inactivated MT was administrated to induced SpA. Blood was collected at 0, 2,4, 6 and 9 weeks to evaluate the antibody titre. Joint, tail and other tissues were collected at 9 weeks. The arthritis score and joint thickness were evaluated every few days. B.C.: blood collection. (C) Antibody titre for IL17A epitope. (D) Binding affinity of the vaccine-induced antibody for recombinant IL17A analysed via ELISA. Antibody of immunised serum at 9 weeks showed specific binding to recombinant IL17A, but not recombinant IL17F. (E) Antibody titre of IL17A epitope-specific IgG subclasses, IgG1 (Th2) and IgG2a (Th1). (F) The balance of Th1/Th2 was evaluated by the IgG2a/IgG1 ratio. IgG2a antibody titre was individually divided by the IgG1 antibody titre. See also online supplemental figure 1.